Proteros Enters into a Collaboration with Bayer
News Jan 10, 2015
Proteros biostructures GmbH has announced that they have entered into a drug discovery research collaboration with Bayer Pharma AG (Bayer). The objective of the collaboration is to identify novel compounds for the treatment of cardiovascular diseases.
Discovery efforts on an undisclosed regulatory membrane protein will be driven by Proteros over a 2 year period to meet predefined milestones, while Bayer would be responsible for further preclinical candidate optimization and clinical development.
Proteros will receive R&D funding, downstream milestones, and royalties on sales of potential resulting commercial products.
The program is based on Proteros´ structure-guided lead discovery platform which combines structure analysis, medicinal chemistry and other discovery technologies to drive potency, selectivity, and safety of novel lead compounds.
Dr. Peter Reinemer, COO of Proteros, commented: “Regulatory membrane proteins are among the most challenging class of targets for structure guided drug discovery approaches. We are very pleased to partner with Bayer in this important initiative for potential new drug candidates for cardiovascular diseases”.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018